AIM:AGY

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Allergy Therapeutics plc engages in the research and development of allergy treatments.


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has Allergy Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AGY's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.2%

AGY

-0.4%

GB Pharmaceuticals

0.1%

GB Market


1 Year Return

7.0%

AGY

14.8%

GB Pharmaceuticals

-15.3%

GB Market

Return vs Industry: AGY underperformed the UK Pharmaceuticals industry which returned 14.8% over the past year.

Return vs Market: AGY exceeded the UK Market which returned -15.3% over the past year.


Shareholder returns

AGYIndustryMarket
7 Day3.2%-0.4%0.1%
30 Day28.4%-0.8%-2.7%
90 Day61.5%14.5%16.9%
1 Year7.0%7.0%19.1%14.8%-11.4%-15.3%
3 Year-44.8%-44.8%45.0%28.0%-3.4%-15.2%
5 Year-37.8%-37.8%86.1%49.3%15.4%-10.3%

Price Volatility Vs. Market

How volatile is Allergy Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Allergy Therapeutics undervalued compared to its fair value and its price relative to the market?

10.92x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AGY's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AGY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AGY is good value based on its PE Ratio (10.9x) compared to the Pharmaceuticals industry average (15.5x).

PE vs Market: AGY is good value based on its PE Ratio (10.9x) compared to the UK market (15x).


Price to Earnings Growth Ratio

PEG Ratio: AGY's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: AGY is good value based on its PB Ratio (1.8x) compared to the GB Pharmaceuticals industry average (3.7x).


Next Steps

Future Growth

How is Allergy Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-90.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGY's earnings are forecast to decline over the next 3 years (-90.7% per year).

Earnings vs Market: AGY's earnings are forecast to decline over the next 3 years (-90.7% per year).

High Growth Earnings: AGY's earnings are forecast to decline over the next 3 years.

Revenue vs Market: AGY's revenue (7% per year) is forecast to grow faster than the UK market (3.4% per year).

High Growth Revenue: AGY's revenue (7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AGY is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Allergy Therapeutics performed over the past 5 years?

25.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AGY has a large one-off gain of £9.2M impacting its December 31 2009 financial results.

Growing Profit Margin: AGY became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: AGY has become profitable over the past 5 years, growing earnings by 25.3% per year.

Accelerating Growth: AGY has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: AGY has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (26%).


Return on Equity

High ROE: AGY's Return on Equity (16.4%) is considered low.


Next Steps

Financial Health

How is Allergy Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AGY's short term assets (£57.5M) exceed its short term liabilities (£15.0M).

Long Term Liabilities: AGY's short term assets (£57.5M) exceed its long term liabilities (£21.7M).


Debt to Equity History and Analysis

Debt Level: AGY's debt to equity ratio (3.9%) is considered satisfactory.

Reducing Debt: AGY's debt to equity ratio has increased from 0.3% to 3.9% over the past 5 years.

Debt Coverage: AGY's debt is well covered by operating cash flow (666.3%).

Interest Coverage: AGY's interest payments on its debt are well covered by EBIT (3.9x coverage).


Balance Sheet


Next Steps

Dividend

What is Allergy Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AGY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AGY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AGY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AGY's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average management tenure


CEO

Manuel Llobet (56yo)

11yrs

Tenure

UK£557,159

Compensation

Mr. Manuel Llobet has been the Chief Executive Officer of Allergy Therapeutics plc since July, 2009. Mr. Llobet joined Allergy in September 2009 following the successful refinancing by Azure Ventures Limit ...


CEO Compensation Analysis

Compensation vs Market: Manuel's total compensation ($USD694.63K) is above average for companies of similar size in the UK market ($USD346.84K).

Compensation vs Earnings: Manuel's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Manuel Llobet
CEO & Executive Director11yrsUK£557.16k0.52% £480.5k
Nicolas Alexander Wykeman
CFO & Director4.08yrsUK£282.95k0.047% £43.3k
Beverly Lees
Group Operations Director4.58yrsno datano data
Murray Skinner
Chief Scientific Officer4.58yrsno datano data
Santiago Puig
Business Development Director10.75yrsno datano data
Sue Baker
Head of Human Resourcesno datano datano data
Simon Piggott
Head of Clinical Science2.83yrsno datano data
Alan Bullimore
Head of Communication & Market Developmentno datano datano data
Russell Picket
Group Financial Controllerno datano datano data
Sara Goldsbrough
Company Secretary3.67yrsno datano data

4.6yrs

Average Tenure

Experienced Management: AGY's management team is considered experienced (4.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Manuel Llobet
CEO & Executive Director11yrsUK£557.16k0.52% £480.5k
Nicolas Alexander Wykeman
CFO & Director4.08yrsUK£282.95k0.047% £43.3k
Babatunde Otulana
Independent Non-Executive Director3.08yrsUK£40.00k0.0078% £7.2k
Peter Jensen
Independent Chairman9.75yrsUK£94.00k0.027% £24.6k
Mary Tavener
Independent Non-Executive Director1.08yrsno datano data
Stephen Smith
Senior Independent Directorno dataUK£49.00k0.12% £112.2k
Johannes Ring
Member of Scientific Advisory Boardno datano datano data
Hendrik Nolte
Chairman of Scientific Advisory Boardno datano datano data
Anthony Frew
Member of Scientific Advisory Boardno datano datano data
Lawrence Du Buske
Member of Scientific Advisory Boardno datano datano data

4.1yrs

Average Tenure

60.5yo

Average Age

Experienced Board: AGY's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Allergy Therapeutics plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Allergy Therapeutics plc
  • Ticker: AGY
  • Exchange: AIM
  • Founded: 2004
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£92.088m
  • Shares outstanding: 637.29m
  • Website: https://www.allergytherapeutics.com

Number of Employees


Location

  • Allergy Therapeutics plc
  • Dominion Way
  • Worthing
  • West Sussex
  • BN14 8SA
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGYT.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDOct 2004
AGYAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPOct 2004

Biography

Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company’s products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil. It also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. The company operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is based in Worthing, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/05 20:53
End of Day Share Price2020/07/03 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.